Next Article in Journal
The Impact of Medial Meniscal Extrusion on Cartilage of the Medial Femorotibial Joint—A Retrospective Analysis Based on Quantitative T2 Mapping at 3.0T
Next Article in Special Issue
Sleep-Disordered Breathing in Patients with Chronic Heart Failure and Its Implications on Real-Time Hemodynamic Regulation, Baroreceptor Reflex Sensitivity, and Survival
Previous Article in Journal
The Tinetti Balance Test Is an Effective Predictor of Functional Decline in Non-Hospitalized Post-COVID-19 Individuals: A Cross-Sectional Study
Previous Article in Special Issue
CPAP Treatment at Home after Acute Decompensated Heart Failure in Patients with Obstructive Sleep Apnea
 
 
Review
Peer-Review Record

Outcome Through the Years of Left-Ventricular Assist Devices Therapy for End-Stage Heart Failure: A Review

J. Clin. Med. 2024, 13(21), 6622; https://doi.org/10.3390/jcm13216622
by Ilaria Tropea *, Giovanni Domenico Cresce, Valerio Sanesi, Loris Salvador and Daniele Zoni *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2024, 13(21), 6622; https://doi.org/10.3390/jcm13216622
Submission received: 30 September 2024 / Revised: 24 October 2024 / Accepted: 2 November 2024 / Published: 4 November 2024
(This article belongs to the Special Issue Current and Emerging Treatment Perspectives in Heart Failure)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors Complete the tex:   - How long is survival with LVAD to Tx heart? - What are the new therapeutic methods (conservative) before LVAD? - What are the recommendations for patients with combined End-Stage Heart failure and End-Stage Kidney Disease? - Is simultaneous Tx recommended and to whom? - What is the recommended dose and which immunosuppressive therapy? - In GIT bleeding, is the HAS BLED score or the CHA2 DS2 VASc score more important - expand that section? Comments on the Quality of English Language

good

Author Response

  • How long is survival with LVAD to Tx heart? Thank you for the advice, I added some lines on different survival rates in the "outcome of patients with LVAD" paragraph (5).
  •  What are the new therapeutic methods (conservative) before LVAD? - What are the recommendations for patients with combined End-Stage Heart failure and End-Stage Kidney Disease? - Is simultaneous Tx recommended and to whom? - What is the recommended dose and which immunosuppressive therapy? - In GIT bleeding, is the HAS BLED score or the CHA2 DS2 VASc score more important - expand that section? Thank you for your advice, but I think these topics have a focus on heart transplantation, not on patients with LVADs.

Reviewer 2 Report

Comments and Suggestions for Authors

The manuscript offers a comprehensive review of Left Ventricular Assist Devices (LVADs) and their role in the treatment of end-stage heart failure. It traces the technological evolution of LVADs and presents a well-rounded discussion on the long-term outcomes and complications associated with their use. While it provides a thorough historical overview, the paper would benefit from a more balanced discussion on the latest advancements and practical clinical management.

Please include a dedicated section on recent and emerging technologies in LVADs. This would provide a forward-looking perspective on how these new innovations could impact future patient outcomes and clinical practice.

There is limited discussion of LVAD therapy in certain subgroups, such as elderly patients or those with significant comorbidities. Consider adding a section on the role of LVADs in these populations, discussing specific challenges, outcomes, and how management strategies might differ. It could be useful to refer to recent data from registries like INTERMACS that address these topics.

A figure summarizing the complications associated with LVADs would add value to the manuscript. 

Moreover, the authors suggestions to minimize such complications would be interesting. 

A minor revision of English is required.

Comments on the Quality of English Language

A minor revision of English is required.

Author Response

The manuscript offers a comprehensive review of Left Ventricular Assist Devices (LVADs) and their role in the treatment of end-stage heart failure. It traces the technological evolution of LVADs and presents a well-rounded discussion on the long-term outcomes and complications associated with their use. While it provides a thorough historical overview, the paper would benefit from a more balanced discussion on the latest advancements and practical clinical management.

Please include a dedicated section on recent and emerging technologies in LVADs. This would provide a forward-looking perspective on how these new innovations could impact future patient outcomes and clinical practice.

Thank you for this advice, I added a few lines on some new techologies being studied (last paragraph). 

There is limited discussion of LVAD therapy in certain subgroups, such as elderly patients or those with significant comorbidities. Consider adding a section on the role of LVADs in these populations, discussing specific challenges, outcomes, and how management strategies might differ. It could be useful to refer to recent data from registries like INTERMACS that address these topics.

Thank you for the advice, I added a section in the "Outcome of patients with LVAD" paragraph. Datas are from recent studies and from the INTERMACS registry.

A figure summarizing the complications associated with LVADs would add value to the manuscript. 

I am working on a figure, but it is not still ready.

Moreover, the authors suggestions to minimize such complications would be interesting. 

A minor revision of English is required.

A revision of english was done.

 

 

Round 2

Reviewer 1 Report

Comments and Suggestions for Authors

No

Author Response

Thank you for your revision.

Reviewer 2 Report

Comments and Suggestions for Authors

Suggestion: A figure summarizing the complications associated with LVADs would add value to the manuscript. 

Authors response: I am working on a figure, but it is not still ready.

Please resubmit when the figure will be ready.

Author Response

Thank you for your suggestion, I submitted the figure.

Back to TopTop